<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cytokinetics Inc — News on 6ix</title>
<link>https://6ix.com/company/cytokinetics-inc</link>
<description>Latest news and press releases for Cytokinetics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cytokinetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355b8978dffbe2df0ebf0c.webp</url>
<title>Cytokinetics Inc</title>
<link>https://6ix.com/company/cytokinetics-inc</link>
</image>
<item>
<title>Cytokinetics to Announce First Quarter Results on May 5, 2026</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-to-announce-first-quarter-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-to-announce-first-quarter-results-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytok</description>
</item>
<item>
<title>Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Mon, 06 Apr 2026 20:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The we</description>
</item>
<item>
<title>Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-four-presentations-at-the-american-college-of-cardiology-annual-scientific-session-and-expo</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-four-presentations-at-the-american-college-of-cardiology-annual-scientific-session-and-expo</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March</description>
</item>
<item>
<title>Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-reports-fourth-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-reports-fourth-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days</description>
</item>
<item>
<title>Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-european-commission-approval-123000674</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-european-commission-approval-123000674</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is</description>
</item>
<item>
<title>Cytokinetics to Announce Fourth Quarter Results on February 24, 2026</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announce-fourth-quarter-results-210000449</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announce-fourth-quarter-results-210000449</guid>
<pubDate>Thu, 12 Feb 2026 21:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of</description>
</item>
<item>
<title>Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-recipients-eighth-annual-123000303</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-recipients-eighth-annual-123000303</guid>
<pubDate>Mon, 09 Feb 2026 12:30:00 GMT</pubDate>
<description>Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eighth annual Communications Grant Program, intended to support increased communications, awareness building and community engagement. Two grants were awarded this year to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) commun</description>
</item>
<item>
<title>Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-myqorzo-aficamten-now-123000704</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-myqorzo-aficamten-now-123000704</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic ca</description>
</item>
<item>
<title>Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-and-olympic-gold-medalist-sydney-mclaughlin-levrone-team-raise-awareness</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-and-olympic-gold-medalist-sydney-mclaughlin-levrone-team-raise-awareness</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s</description>
</item>
<item>
<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-20</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-20</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted</description>
</item>
<item>
<title>CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)</title>
<link>https://6ix.com/company/cytokinetics-inc/news/caremed-has-been-selected-as-a-national-specialty-pharmacy-provider-for-myqorzotm-aficamten</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/caremed-has-been-selected-as-a-national-specialty-pharmacy-provider-for-myqorzotm-aficamten</guid>
<pubDate>Mon, 12 Jan 2026 21:30:00 GMT</pubDate>
<description>NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.1 “MYQORZO represents a meaningful advancement for adults living with obstructive hypertrophic cardiomyopathy, and we are extremely excited to partner closely with the team</description>
</item>
<item>
<title>Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and</description>
</item>
<item>
<title>Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-fda-approval-myqorzotm-aficamten-treatment-adults-symptomatic</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-fda-approval-myqorzotm-aficamten-treatment-adults-symptomatic</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of</description>
</item>
<item>
<title>Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-nmpa-approval-myqorzor-aficamten-china-patients-obstructive</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-nmpa-approval-myqorzor-aficamten-china-patients-obstructive</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in</description>
</item>
<item>
<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-16</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-16</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted</description>
</item>
<item>
<title>Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-positive-chmp-opinion-myqorzor-aficamten-treatment-obstructive</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-announces-positive-chmp-opinion-myqorzor-aficamten-treatment-obstructive</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:</description>
</item>
<item>
<title>Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-supports-american-heart-association-initiative-improve-care-people</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-supports-american-heart-association-initiative-improve-care-people</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.</description>
</item>
<item>
<title>Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-presents-additional-data-maple-hcm-hypertrophic-cardiomyopathy-medical</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-presents-additional-data-maple-hcm-hypertrophic-cardiomyopathy-medical</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac</description>
</item>
<item>
<title>Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-reports-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-reports-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews</description>
</item>
<item>
<title>Cytokinetics to Participate in November Investor Conferences</title>
<link>https://6ix.com/company/cytokinetics-inc/news/cytokinetics-participate-november-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/cytokinetics-inc/news/cytokinetics-participate-november-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company</description>
</item>
</channel>
</rss>